Comprehensive Characterization of Common and Cancer-Specific Differently Expressed LncRNAs in Urologic Cancers

Overview

Journal Comput Math Methods Med

Publisher Hindawi

Specialty Medical Informatics

Date 2021 Aug 2

PMID 34335862

Citations 5

Authors

You-Ji Yan

Ling Zhang

Jia-Jie Zhou

Zhong-Jun Chen

Yi-Xiang Liao

Jin-Min Zeng

Hao Shen

Affiliations

Soon will be listed here.

Abstract

Urologic cancers, comprising prostate carcinoma (PCa), renal cell carcinoma (RCC), and bladder carcinoma (BCa), were the commonly occurred carcinoma amid males. Long noncoding RNAs (lncRNAs) with the length of more than 200 nt functioned importantly in physiological and pathological advancement. Nevertheless, further investigation regarding lncRNA expression feature and function in urologic cancers should be essential. This study is aimed at uncovering the roles of the differently expressed lncRNAs in urologic cancers. The data of gene expression levels was downloaded from lncRNAtor datasets. The lncRNA expression pattern existing in different urologic cancers was assessed by hierarchical clustering analysis. Gene Ontology (GO) analysis and KEGG pathway analysis were separately applied to evaluate the biological function and process and the biological pathways involving differently expressed lncRNAs. Our results indicated that 18 lncRNA expressions were increased, and 16 lncRNA expressions were reduced in urologic cancers after comparison with that in normal tissues. Moreover, our results demonstrated 61, 422, 137, and 281 lncRNAs were specifically dysregulated in bladder cancer (BLCA), kidney renal clear cell cancer (KIRC), kidney renal papillary cell cancer (KIRP), and prostate adenocarcinoma (PRAD), respectively. Bioinformatics analysis showed that differently expressed lncRNAs displayed crucially in urologic cancers. The prognostic value of common and cancer-specific differently expressed lncRNAs, such as PVT1, in cancer outcomes, was emphasized here. Our research has deeply unearthed the mechanism of differently expressed lncRNAs in urologic cancers development.

Citing Articles

Identification of cuproptosis-related lncRNAs signature for predicting the prognosis in patients with kidney renal clear cell carcinoma.

He Y, Zhang H, Li J, Zhou H, Wang F, Zhang G J Genet Eng Biotechnol. 2024; 22(1):100338.

PMID: 38494257 PMC: 10860879. DOI: 10.1016/j.jgeb.2023.100338.

A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer.

Xie S, He J, Feng B, Rao D, Wang S, He Y Heliyon. 2023; 9(5):e15897.

PMID: 37215925 PMC: 10199227. DOI: 10.1016/j.heliyon.2023.e15897.

Potential upstream lncRNA-miRNA-mRNA regulatory network of the ferroptosis-related gene in renal cell carcinoma.

Xu F, Ji S, Yang L, Li Y, Shen P Transl Androl Urol. 2023; 12(1):33-57.

PMID: 36760866 PMC: 9906110. DOI: 10.21037/tau-22-663.

N‑methyladenosine‑induced long non‑coding RNA PVT1 regulates the miR‑27b‑3p/BLM axis to promote prostate cancer progression.

Chen B, Liu C, Long H, Bai G, Zhu Y, Xu H Int J Oncol. 2022; 62(1).

PMID: 36484368 PMC: 9747193. DOI: 10.3892/ijo.2022.5464.

Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?.

Trevisani F, Floris M, Vago R, Minnei R, Cinque A Cells. 2022; 11(10).

PMID: 35626699 PMC: 9139553. DOI: 10.3390/cells11101658.

References

Colombo T, Farina L, Macino G, Paci P . PVT1: a rising star among oncogenic long noncoding RNAs. Biomed Res Int. 2015; 2015:304208. PMC: 4391155. DOI: 10.1155/2015/304208. View

Pan Y, Fang Y, Xie M, Liu Y, Yu T, Wu X . LINC00675 Suppresses Cell Proliferation and Migration via Downregulating the H3K4me2 Level at the SPRY4 Promoter in Gastric Cancer. Mol Ther Nucleic Acids. 2020; 22:766-778. PMC: 7595884. DOI: 10.1016/j.omtn.2020.09.038. View

Verhaegh G, Verkleij L, Vermeulen S, den Heijer M, Witjes J, Kiemeney L . Polymorphisms in the H19 gene and the risk of bladder cancer. Eur Urol. 2008; 54(5):1118-26. DOI: 10.1016/j.eururo.2008.01.060. View

Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C . Expression of Long Noncoding RNA Promotes Glycolysis in Breast Cancer. Cancer Res. 2018; 78(16):4524-4532. PMC: 6126676. DOI: 10.1158/0008-5472.CAN-17-0385. View

Wei W, Leng J, Shao H, Wang W . High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients. Int J Clin Exp Med. 2015; 8(9):16606-12. PMC: 4659079. View

He W, Zhong G, Jiang N, Wang B, Fan X, Chen C . Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis. J Clin Invest. 2018; 128(2):861-875. PMC: 5785244. DOI: 10.1172/JCI96218. View

Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi M . LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019; 18(1):141. PMC: 6785865. DOI: 10.1186/s12943-019-1064-5. View

Xiao Z, Han L, Lee H, Zhuang L, Zhang Y, Baddour J . Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. Nat Commun. 2017; 8(1):783. PMC: 5627275. DOI: 10.1038/s41467-017-00902-z. View

Park C, Yu N, Choi I, Kim W, Lee S . lncRNAtor: a comprehensive resource for functional investigation of long non-coding RNAs. Bioinformatics. 2014; 30(17):2480-5. DOI: 10.1093/bioinformatics/btu325. View

10.

Hu X, Zhang L, Tian J, Ma J . Long non-coding RNA PART1 predicts a poor prognosis and promotes the malignant progression of pancreatic cancer by sponging miR-122. World J Surg Oncol. 2021; 19(1):122. PMC: 8053290. DOI: 10.1186/s12957-021-02232-3. View

11.

Prensner J, Rubin M, Wei J, Chinnaiyan A . Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med. 2012; 4(127):127rv3. PMC: 3799996. DOI: 10.1126/scitranslmed.3003180. View

12.

Shigeyasu K, Toden S, Ozawa T, Matsuyama T, Nagasaka T, Ishikawa T . The PVT1 lncRNA is a novel epigenetic enhancer of MYC, and a promising risk-stratification biomarker in colorectal cancer. Mol Cancer. 2020; 19(1):155. PMC: 7643275. DOI: 10.1186/s12943-020-01277-4. View

13.

Lan Y, Xiao X, He Z, Luo Y, Wu C, Li L . Long noncoding RNA OCC-1 suppresses cell growth through destabilizing HuR protein in colorectal cancer. Nucleic Acids Res. 2018; 46(11):5809-5821. PMC: 6009600. DOI: 10.1093/nar/gky214. View

14.

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

15.

He F, Song Z, Chen H, Chen Z, Yang P, Li W . Long noncoding RNA PVT1-214 promotes proliferation and invasion of colorectal cancer by stabilizing Lin28 and interacting with miR-128. Oncogene. 2018; 38(2):164-179. PMC: 6329639. DOI: 10.1038/s41388-018-0432-8. View

16.

Xing Z, Li S, Liu Z, Zhang C, Meng M, Bai Z . The long non-coding RNA LINC00473 contributes to cell proliferation via JAK-STAT3 signaling pathway by regulating miR-195-5p/SEPT2 axis in prostate cancer. Biosci Rep. 2020; 40(9). PMC: 7494984. DOI: 10.1042/BSR20191850. View

17.

Guo J, Hao C, Wang C, Li L . Long noncoding RNA PVT1 modulates hepatocellular carcinoma cell proliferation and apoptosis by recruiting EZH2. Cancer Cell Int. 2018; 18:98. PMC: 6042336. DOI: 10.1186/s12935-018-0582-3. View

18.

Zhang Y, Pitchiaya S, Cieslik M, Niknafs Y, Tien J, Hosono Y . Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet. 2018; 50(6):814-824. PMC: 5980762. DOI: 10.1038/s41588-018-0120-1. View

19.

Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q . LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling. Cell Death Dis. 2018; 9(7):742. PMC: 6030066. DOI: 10.1038/s41419-018-0793-5. View

20.

Liu E, Liu Z, Zhou Y, Mi R, Wang D . Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med. 2016; 8(11):20565-72. PMC: 4723819. View